Medifast, Inc.
MED · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $89,409 | $105,555 | $115,728 | $119,003 |
| % Growth | -15.3% | -8.8% | -2.8% | – |
| Cost of Goods Sold | $27,250 | $28,911 | $31,483 | $30,784 |
| Gross Profit | $62,159 | $76,644 | $84,245 | $88,219 |
| % Margin | 69.5% | 72.6% | 72.8% | 74.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $66,240 | $77,710 | $85,507 | $87,510 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $66,240 | $77,710 | $85,507 | $87,510 |
| Operating Income | -$4,081 | -$1,066 | -$1,262 | $709 |
| % Margin | -4.6% | -1% | -1.1% | 0.6% |
| Other Income/Exp. Net | $1,424 | $3,941 | $1,788 | $566 |
| Pre-Tax Income | -$2,657 | $2,875 | $526 | $1,275 |
| Tax Expense | -$396 | $395 | $1,298 | $474 |
| Net Income | -$2,261 | $2,480 | -$772 | $801 |
| % Margin | -2.5% | 2.3% | -0.7% | 0.7% |
| EPS | -0.21 | 0.23 | -0.07 | 0.07 |
| % Growth | -191.3% | 428.6% | -200% | – |
| EPS Diluted | -0.21 | 0.22 | -0.07 | 0.07 |
| Weighted Avg Shares Out | 10,991 | 10,991 | 10,948 | 10,938 |
| Weighted Avg Shares Out Dil | 10,991 | 11,060 | 10,948 | 10,983 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,426 | $1,369 | $1,301 | $953 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3,452 | $4,045 | $3,280 | $3,185 |
| EBITDA | $795 | $2,979 | $2,018 | $3,894 |
| % Margin | 0.9% | 2.8% | 1.7% | 3.3% |